Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.

Autor: Chen LS; Siteman Cancer Center, Institute of Public Health, and Department of Psychiatry, Washington University School of Medicine, St. Louis, MI., Zawertailo L; Nicotine Dependence Service, Centre for Addiction and Mental Health, and Dept. of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada., Piasecki TM; Department of Psychological Sciences, University of Missouri, Columbia, MI., Kaprio J; Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland., Foreman M; Pulmonary and Critical Care Medicine, Morehouse School of Medicine, Atlanta, GA., Elliott HR; MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK., David SP; Department of Medicine, Stanford University, Stanford, CA., Bergen AW; BioRealm, Culver City, CA., Baurley JW; BioRealm, Culver City, CA., Tyndale RF; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, and Departments of Pharmacology & Toxicology and Psychiatry, University of Toronto, Toronto, Ontario, Canada., Baker TB; Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI., Bierut LJ; Siteman Cancer Center, Institute of Public Health, and Department of Psychiatry, Washington University School of Medicine, St. Louis, MI., Saccone NL; Department of Genetics, Washington University School of Medicine, St. Louis, MI.
Jazyk: angličtina
Zdroj: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco [Nicotine Tob Res] 2018 Mar 06; Vol. 20 (4), pp. 414-424.
DOI: 10.1093/ntr/ntx097
Abstrakt: Implications: This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.
Databáze: MEDLINE